People: Orthofix International NV (OFIX.O)

OFIX.O on Nasdaq

26.82USD
21 May 2013
Price Change (% chg)

$0.18 (+0.68%)
Prev Close
$26.53
Open
$26.72
Day's High
$27.38
Day's Low
$26.70
Volume
262,962
Avg. Vol
177,082
52-wk High
$45.62
52-wk Low
$25.30

Search Stocks

Summary

Name Age Since Current Position

James Gero

 68 2004 Chairman of the Board

Bradley Mason

 2013 President, Chief Executive Officer

Emily Buxton

 36 2013 Chief Financial Officer

Brian McCollum

 37 2012 President - Spine Global Business Unit

Jeffrey Schumm

 51 2010 Senior Vice President, General Counsel, Corporate Secretary

Michael Finegan

 49 2012 Senior Vice President - Corporate Development; President - Biologics

Maria Sainz

 47 2012 Director

Davey Scoon

 66 2011 Independent Director

Guy Jordan

 63 2004 Non-Executive Independent Director

Michael Mainelli

 50 2009 Non-Executive Independent Director

Walter von Wartburg

 72 2004 Non-Executive Independent Director

Kenneth Weisshaar

 61 2004 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

James Gero

 Mr. James F. Gero is Chairman of Orthofix International N.V., since December 2, 2004. He has been a Director of Orthofix International N.V. since 1998. He is a director of publicly-traded companies Intrusion, Inc., where he serves as chairman of the compensation committee and a member of the audit committee, and Drew Industries, Inc., where he serves as the lead independent director and a member of the audit committee. He is also a private investor.

Bradley Mason

 Mr. Bradley R. Mason is President, Chief Executive Officer of Orthofix International NV. Mr. Mason rejoins the Company after previously serving as its Group President, North America from June 2008 through October 2009, and as a Strategic Advisor from November 2009 through October 2010, when he retired from the Company. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003, when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 25 years of experience in the medical device industry, some of which were spent with dj Orthopedics (formally DonJoy) where he was a founder and held the position of Executive Vice President. Since his retirement from Orthofix in 2010, he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13, 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College.

Emily Buxton

 Ms. Emily V. Buxton has been appointed as Chief Financial Officer of Orthofix International N.V., effective April 4, 2013. Ms. Buxton joined Orthofix's corporate finance group in 2003 as a Senior SEC and Consolidations Accountant. After advancing to the position of Vice President, Controller, she served as Chief Financial Officer of Global Orthopedics for Orthofix from 2010 to the time of her appointment as Interim Chief Financial Officer. Prior to joining Orthofix, Ms. Buxton worked for two public companies in Securities and Exchange Commission reporting and prior to that she worked in public accounting. She received her Bachelors of Arts degree in Accounting from Columbia College in Columbia, SC.

Brian McCollum

 Mr. Brian McCollum is President - Spine Global Business Unit of Orthofix International N.V. He joined Orthofix’s corporate finance group in 2001 advancing to the position of Corporate Controller. In 2006, Mr. McCollum was named Vice President of Finance, Americas, and 2 years later became Vice President of International Finance and Group Treasurer. Prior to joining Orthofix, Mr. McCollum was a Senior Audit Associate with PriceWaterhouseCoopers. He received his Bachelors degree in Business Administration, with concentration in Accounting, from St. Andrews Presbyterian College.

Jeffrey Schumm

 Mr. Jeffrey M. Schumm is Senior Vice President, General Counsel, Corporate Secretary of Orthofix International NV. Mr. Schumm joined Orthofix International N.V. as Assistant General Counsel in January 2007, and was promoted to Senior Vice President, General Counsel and Corporate Secretary in October 2010. From 2004 to 2006, Mr. Schumm served as Vice President and General Counsel for Regeneration Technologies, Inc. Earlier in his career, he served as an Assistant Attorney General for the State of Florida, as an associate at Holland & Knight LLP and as a Staff Attorney at the Supreme Court of Florida. Mr. Schumm received his Bachelors of Science in Electrical Engineering and Masters in Business Administration from Lehigh University, and he is a magna cum laude graduate of the Florida State University College of Law.

Michael Finegan

 Mr. Michael M. Finegan is Senior Vice President - Corporate Development and President - Biologics of Orthofix International NV. Mr. Finegan joined Orthofix International N.V. in June 2006 as Vice President of Corporate Development. Mr. Finegan was named President, Biologics in March 2009. Prior to joining Orthofix, Mr. Finegan spent sixteen years as an executive with Boston Scientific in a number of different operating and strategic roles, most recently as Vice President of Corporate Sales. Earlier in his career, Mr. Finegan held sales and marketing roles with Marion Laboratories and spent three years in banking with First Union Corporation (Wachovia). Mr. Finegan earned a BA in Economics from Wake Forest University.

Maria Sainz

 Ms. Maria Degois Sainz is the Director of Orthofix International N.V. In April 2008, she became President and Chief Executive Officer of Concentric Medical, Inc., a company developing and commercializing devices to perform mechanical clot removal post-stroke. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, Ms. Sainz was the Vice President of Global Marketing – Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Masters Degree in International Management from American Graduate School of International Management. Ms. Sainz became a Director of The Spectranetics Corporation, a publicly-traded medical device company, in November 2010.

Davey Scoon

 Mr. Davey S. Scoon is Independent Director of Orthofix International N.V., since August 16, 2011. Mr. Scoon serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981. He also serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company consisting of 22 mutual funds, where he has been a director since 2006. Mr. Scoon is the Chairman of the Audit Committee of pharmaceutical companies AMAG Pharmaceuticals, Inc. and Cardiokine, Inc., where he has been a director since 2006 and 2005, respectively. He has been an Adjunct Assistant Professor at Tufts University School of Medicine since 2005. He also previously served as the Chairman of the Audit Committee of NitroMed, Inc., a public pharmaceutical company, from 2003 to 2009, and a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a pharmaceutical company, from 2006 to 2009. From 2003 to 2005, Mr. Scoon was Chief Administrative and Financial Officer of Tom’s of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School. He is a lecturer at the University of Wisconsin-Madison.

Guy Jordan

 Dr. Guy J. Jordan, Ph.D., is Non-executive Independent Director of Orthofix International N.V., since December 7, 2004. Most recently, from 1996 to 2002, Dr. Jordan served as a Group President at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard’s global oncology business and functional responsibility for all of Bard’s research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of private health care companies EndoGastric Solutions, Inc. and Catheter Connections, Inc.

Michael Mainelli

 Mr. Michael R. Mainelli, Jr., is Non-executive Independent Director of Orthofix International N.V. Since August 18, 2009 he has served as President and Chief Executive Officer of Active Implants Corporation, an early stage company developing a platform technology for orthopedic hip and knee markets, where he has also been a Director since 2008. Between 2005 and 2006 he was an executive officer and Sector President, Medical Devices for Intermagnetics General Corporation. Between 1996 and 2004 he was an executive officer of Stryker Corporation, serving as President-Stryker Spine, President-Stryker Japan, and Vice President, Corporate Development and Assistant to the Chairman. Between 1984 and 1996 he was employed by GE in a variety of operations and marketing roles, ultimately serving as a marketing and product management executive in the Global Magnetic Resonance Imaging Business at GE Medical Systems, now called GE Healthcare. Mr. Mainelli holds a MBA from the University of Chicago, a MSE from the University of Pennsylvania, and a BSME from Northeastern University.

Walter von Wartburg

 Dr. Walter P. von Wartburg, Ph.D., is Non-Executive Independent Director of Orthofix International N.V., since June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a Professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis, in each case with a focus on corporate communication matters.

Kenneth Weisshaar

 Mr. Kenneth R. Weisshaar is Non-Executive Independent Director of Orthofix International N.V. in December 7, 2004. From 2000 to 2002, Mr. Weisshaar served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Prior to that, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a Bachelor of Science degree from Massachusetts Institute of Technology and an MBA from Harvard Business School. He also serves on the board, and as chair of the board’s audit committee, of CAS Medical Systems, Inc., a publicly traded manufacturer of medical devices for non-invasive patient monitoring. Prior to its acquisition in 2007, he also served for four years on the board of Digene Corporation, a publicly traded biotechnology company, where he was chair of the audit committee and a member of the compensation committee. Mr. Weisshaar also serves on the board of CenterLight Health System, one of the non-for-profit long-term care providers in New York State.

Basic Compensation

Name Fiscal Year Total

James Gero

 --

Bradley Mason

 1,432,190

Emily Buxton

 --

Brian McCollum

 911,940

Jeffrey Schumm

 --

Michael Finegan

 515,388

Maria Sainz

 --

Davey Scoon

 --

Guy Jordan

 --

Michael Mainelli

 --

Walter von Wartburg

 --

Kenneth Weisshaar

 --
As Of 30 Dec 2011

Insider Trading

Name Shares Traded Price

MAINELLI MICHAEL R JR

 500 $26.36

GERO JAMES F

 20,000 $26.37

BUXTON EMILY

 2,500 $0.00

MASON BRADLEY R

 10,000 $0.00

VATERS ROBERT S

 3,000 $35.97

GERO JAMES F

 1,836 $29.95

MAINELLI MICHAEL R JR

 500 $29.95

JORDAN GUY J

 467 $29.95

SCOON DAVEY STEWART

 626 $29.95

WEISSHAAR KENNETH R

 542 $29.95

SAINZ MARIA

 3,500 $0.00

FERRARI LUIGI

 10,460 $28.95

FERRARI LUIGI

 10,460 $41.40

FERRARI LUIGI

 4,487 $28.95

FERRARI LUIGI

 4,487 $41.40

FERRARI LUIGI

 4,323 $41.40

FERRARI LUIGI

 4,323 $25.01

FERRARI LUIGI

 2,675 $41.20

FERRARI LUIGI

 2,033 $23.58

FERRARI LUIGI

 2,675 $32.18

FINEGAN MICHAEL M

 3,000 $41.20

FINEGAN MICHAEL M

 3,000 $18.44

FERRARI LUIGI

 2,033 $41.40

FERRARI LUIGI

 677 $25.01

FERRARI LUIGI

 677 $41.40
» Full list on Insider Trading
Search Stocks